Biotechnology

WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates th...

2022-12-21 08:00 2406

Sanisure Announces the Acquisition of a Leading Silicone Extrusion Facility in Twinsburg, Ohio

CAMARILLO, Calif., Dec. 21, 2022 /PRNewswire/ -- Sanisure, a leading, vertically-integrated player in the single- use bioprocessing technology space, is pleased to announce the acquisition of Medical Elastomer Development, Inc ("MED") a silicone extrusion facility from Q Holding, a 3i portfolio c...

2022-12-21 00:06 2250

AstraZenca, G42 Healthcare enter strategic partnership to manufacture pharmaceutical products in Abu Dhabi

ABU DHABI, UAE, Dec. 20, 2022 /PRNewswire/ -- Building on the ongoing efforts of the Department of Health –Abu Dhabi (DoH) in spearheading Abu Dhabi's healthcare ecosystem, AstraZeneca, a science-led biopharmaceutical and one of the top 10 biopharma companies globally, and G42 Healthcare, an AI-p...

2022-12-20 23:16 2535

Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia

CAMBRIDGE, Mass., Dec. 20, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese National Medical Products Administration (NMPA) and the Australian Therapeutic ...

2022-12-20 20:00 2462

The Top 8 Best Places to Work in Philippines for 2022 revealed

MANILA, Philippines , Dec. 20, 2022 /PRNewswire/ -- Amway, Fujitsu, Multicare, Novo Nordisk, Diageo, Kusum, Schindler and Universal Robina are recognized as the top 8 best places to work inPhilippines for 2022 according to the annual prestigious "Best Places to Work" certification program.  Amwa...

2022-12-20 19:56 2917

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute ofMateria Medica (the "SIMM") and Wuhan Institute of Virology (the "WIV"), Chines...

2022-12-20 19:21 2124

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

SHANGHAI and MOSCOW, Dec. 20, 2022 /PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, today announced the company has entered into an licensing agreement with the Russian pharmaceutical company Binnopharm Group, for 9M...

2022-12-20 17:00 2322

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapie...

2022-12-19 23:07 2255

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board. He joins Prof. Jianzhu Chen of theMassach...

2022-12-19 22:00 1980

SeekIn Receives CE-IVD Mark Approval for PanCanSeek® Cancer Mutation Detection Kit

First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit...

2022-12-19 21:00 1631

Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives

--The issue date of the patent will be January 3, 2023 by the United States Patent and Trademark Office (USPTO). The patent number is 11,541,071 -- The issued patent covers ASC10 and its derivatives, and their uses to treat virus infections including SARS-CoV-2, monkeypox virus and respiratory s...

2022-12-19 18:10 2619

TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

HEFEI, China, Dec. 17, 2022 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (Hefei, China), an innovative biotech company dedicated to the discovery of novel immunotherapeutic drugs and a leader in NK cell research globally, today announced that the U.S. Food and Drug Administration (FDA) has cleared i...

2022-12-17 21:30 2843

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

* Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform * Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Gra...

2022-12-16 19:56 3390

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of ...

2022-12-16 14:49 5065

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of$150 million aggregate principal amount of its ...

2022-12-16 14:18 4101

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Depar...

2022-12-16 08:44 2116

Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of$125 million aggregate principal amount of convertible...

2022-12-15 23:43 3845

BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy

* A leader in creating jobs through the advancement of RNA-based therapeutics * A contributor to a high employment rate in Korea's healthcare industry BOSTON, Dec. 15, 2022 /PRNewswire/ -- BIORCHESTRA ("BIORCHESTRA" or the "Company"), a RNA therapeutics company with offices in Daejeon, South K...

2022-12-15 21:00 1507

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Ph...

2022-12-15 14:00 2711

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as "Biosyngen") made an announcement on the approval granted by the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) for the company's IND appl...

2022-12-15 13:08 4117
1 ... 134135136137138139140 ... 307